{"id":8184,"date":"2021-03-31T09:46:32","date_gmt":"2021-03-31T16:46:32","guid":{"rendered":"https:\/\/depts.washington.edu\/pandemicalliance\/?p=8184"},"modified":"2021-04-01T09:47:26","modified_gmt":"2021-04-01T16:47:26","slug":"efficacy-of-chadox1-ncov-19-azd1222-vaccine-against-sars-cov-2-variant-of-concern-202012-01-b-1-1-7-an-exploratory-analysis-of-a-randomised-controlled-trial","status":"publish","type":"post","link":"https:\/\/depts.washington.edu\/pandemicalliance\/2021\/03\/31\/efficacy-of-chadox1-ncov-19-azd1222-vaccine-against-sars-cov-2-variant-of-concern-202012-01-b-1-1-7-an-exploratory-analysis-of-a-randomised-controlled-trial\/","title":{"rendered":"Efficacy of ChAdOx1 NCoV-19 (AZD1222) Vaccine against SARS-CoV-2 Variant of Concern 202012\/01 (B.1.1.7): An Exploratory Analysis of a Randomised Controlled Trial"},"content":{"rendered":"<ul>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">Post-hoc analysis of the Oxford-AstraZeneca vaccine indicated that clinical vaccine efficacy against symptomatic, PCR-positive infection was 70.4% for the B.1.1.7 variant and 81.5% for non-B.1.1.7 lineages (not including the B.1.351 variant). Neutralization activity via vaccine-induced antibodies <\/span><i><span style=\"font-weight: 400\">in vitro<\/span><\/i><span style=\"font-weight: 400\"> was also lower against the B.1.1.7 variant (geometric mean ratio 8.9).\u00a0Participants 18 and older in efficacy cohorts (n=8534) were included in the analysis, and received either the COVID-19 vaccine or a control meningococcal conjugate vaccine. <\/span><i><span style=\"font-weight: 400\">[EDITORIAL NOTE: This paper was summarized as a pre-print on February 5, 2021]<\/span><\/i><\/li>\n<\/ul>\n<p><i><span style=\"font-weight: 400\">Emary et al. (Mar 30, 2021). Efficacy of ChAdOx1 NCoV-19 (AZD1222) Vaccine against SARS-CoV-2 Variant of Concern 202012\/01 (B.1.1.7): An Exploratory Analysis of a Randomised Controlled Trial. The Lancet. <\/span><\/i><a href=\"https:\/\/doi.org\/10.1016\/S0140-6736(21)00628-0\"><span style=\"font-weight: 400\">https:\/\/doi.org\/10.1016\/S0140-6736(21)00628-0<\/span><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Post-hoc analysis of the Oxford-AstraZeneca vaccine indicated that clinical vaccine efficacy against symptomatic, PCR-positive infection was 70.4% for the B.1.1.7 variant and 81.5% for non-B.1.1.7 lineages (not including the B.1.351 variant). Neutralization activity via vaccine-induced antibodies in vitro was also lower against the B.1.1.7 variant (geometric mean ratio 8.9).\u00a0Participants 18 and older in efficacy cohorts&#8230;<\/p>\n<div><a class=\"more\" href=\"https:\/\/depts.washington.edu\/pandemicalliance\/2021\/03\/31\/efficacy-of-chadox1-ncov-19-azd1222-vaccine-against-sars-cov-2-variant-of-concern-202012-01-b-1-1-7-an-exploratory-analysis-of-a-randomised-controlled-trial\/\">Read more<\/a><\/div>\n","protected":false},"author":8,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[6],"tags":[33],"topic":[31],"class_list":["post-8184","post","type-post","status-publish","format-standard","hentry","category-article-summary","tag-vaccines","topic-vaccines-and-immunity"],"_links":{"self":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/8184","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/comments?post=8184"}],"version-history":[{"count":1,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/8184\/revisions"}],"predecessor-version":[{"id":8185,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/8184\/revisions\/8185"}],"wp:attachment":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/media?parent=8184"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/categories?post=8184"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/tags?post=8184"},{"taxonomy":"topic","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/topic?post=8184"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}